Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy
Status:
Completed
Trial end date:
2016-08-31
Target enrollment:
Participant gender:
Summary
The Membranous Nephropathy is one of the most common cause of Nephrotic Syndrome of adults.
In 2/3 of patients the cause of the disease is idiopathic. This can also be referred to as
idiopathic membranous nephropathy (IMN).The most of these patients are treated by non
immunosuppressive symptomatic treatment (NIST): antiproteinuric and antihypertensive blocking
the rennin-angiotensine system. However, the patients resistant to antiproteinuric treatment
risk to develop an end stage renal disease (ESRD).
Rituximab has been recently used in patients suffering of nephrotic syndrome related to IMN
in four international studies. Rituximab appears effective and safe in reducing proteinuria
in nearly 60% of patients.
The primary outcome of the investigators prospective randomized study is to determine whether
or not the Rituximab associated with NIST is more effective than non immunologic symptomatic
treatment alone in inducing long term remission of proteinuria.